September 17, 2015 — Siemens Healthcare announced that the U.S. Food and Drug Administration (FDA) recently cleared the Mammomat Fusion – the latest addition to the Siemens family of full-field digital mammography systems. The new system offers premium product features to address the specific needs of volume screening centers and small to medium-sized hospitals.
The Mammomat Fusion mammography system features a new-generation cesium-iodide detector – an innovative, layered configuration of the photo diodes within the detector that enables more efficient utilization of the radiation dose. The result: high image quality at a patient dose at or below the range of other full-field digital mammography systems; an even lower dose is delivered in cases where the patient’s breast thickness exceeds 50 mm. And the system’s large image matrix of 23 x 30 cm makes the Mammomat Fusion the right choice for screening various breast sizes.
In addition to the new detector, the system features selected technologies developed for Siemens’ premium Mammomat Inspiration platform. The OpDose feature ensures the radiation dose can be tailored for each patient without compromising image quality. The technologist can select the appropriate parameters in accordance with the patient’s breast size and density. The screening process is also simplified for clinical staff thanks to the compact, syngo-based Acquisition Workstation (AWS). Users can load patient data directly from the radiology information system without requiring a second workstation. Clinical personnel also benefit from an intuitive, automated workflow. The system is ready for scanning with just one click, with easy manual positioning.
In tomosynthesis mode, the Mammomat Inspiration X-ray tube rotates in a circular motion around the breast to acquire an image every two degrees while moving through an angular range of 50 degrees; the resulting 25 projections are reconstructed as 3-D digital breast tomosynthesis images.
For more information: www.usa.siemens.com/healthcare
April 23, 2024 
